A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

PHASE2RecruitingINTERVENTIONAL

Enrollment

224

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL

mRNA-1647

Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (1)

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY